Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €112.89B | 30.3x | 1.33 | €441.15 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Regeneron Pharma | Vienna | Healthcare | Biotechnology & Medical Research | €105.83B | 29.1x | -3.35 | €877.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Moderna | Vienna | Healthcare | Biotechnology & Medical Research | €42.48B | -7.6x | 0.04 | €113.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €35.96B | 28.9x | 0.75 | €168.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €24.28B | -77.7x | -1.85 | €356.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €18.10B | 158.7x | -1.78 | €79.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €14.85B | 20.9x | 6.32 | €266 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €8.51B | 27.2x | -5.24 | €38.67 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Morphosys | Vienna | Healthcare | Biotechnology & Medical Research | €2.55B | -5.2x | 0.01 | €66.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €1.59B | -17.2x | -0.74 | €8.68 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.54B | 5.5x | 0.28 | €35.69 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
CureVac NV | Vienna | Healthcare | Biotechnology & Medical Research | €711.77M | -2.5x | -0.15 | €3.47 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Valneva | Vienna | Healthcare | Biotechnology & Medical Research | €443.06M | -18x | -0.21 | €3.11 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |
Medigene | Vienna | Healthcare | Biotechnology & Medical Research | €33.46M | -1.7x | 0.03 | €1.12 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |